Kazuyuki Atarashi

Title: Kazuyuki Atarashi: Innovator in Anti-Cancer Antibody Development

Introduction

Kazuyuki Atarashi is a prominent inventor based in Komagane, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies with anti-cancer activity. His innovative work has the potential to impact cancer treatment and improve patient outcomes.

Latest Patents

Kazuyuki Atarashi holds a patent for an "Antibody having anti-cancer activity." This invention utilizes an SST-REX method to select a cDNA encoding a protein expressed on a cell surface or secreted from a cancer cell line. Monoclonal antibodies against the protein encoding the selected cDNA were prepared. The in vitro and in vivo anti-cancer activities and binding to various cancer cell lines were examined. As a result, a monoclonal antibody that binds to a PODXL2 protein, which exhibits excellent anti-cancer activities, was discovered. Furthermore, a region including an epitope of the antibody was successfully identified, and the amino acid sequences of variable regions of a light chain and a heavy chain were determined.

Career Highlights

Kazuyuki Atarashi is associated with Actgen Inc., where he continues to advance his research in antibody development. His work has garnered attention for its innovative approach to tackling cancer through targeted therapies.

Collaborations

Kazuyuki has collaborated with notable colleagues, including Masunori Kajikawa and Masahito Sugiura. Their combined expertise contributes to the success of their research initiatives.

Conclusion

Kazuyuki Atarashi's contributions to the field of anti-cancer antibodies highlight his role as an innovator in biotechnology. His work not only advances scientific knowledge but also holds promise for future cancer therapies.